What is a common contraindication for thrombolytic therapy in stroke patients?

What is a common contraindication for thrombolytic therapy in stroke patients?

• A. A history of hemorrhagic stroke
• B. Age over 75 years
• C. Previous ischemic stroke
• D. Diabetes mellitus

Answer: (A)

A common contraindication for thrombolytic therapy in stroke patients is a history of hemorrhagic stroke. This condition poses significant risk when considering thrombolytic treatment because these medications work by dissolving blood clots that are obstructing blood flow to the brain. However, if a patient has previously experienced a hemorrhagic stroke, there is a heightened risk of re-bleeding or exacerbating any existing vascular vulnerabilities. Therefore, the presence of a history of hemorrhagic stroke necessitates careful consideration and often excludes a patient from receiving thrombolytic therapy, as the potential for severe complications is high. Other factors such as age over 75 years or a history of previous ischemic stroke are not absolute contraindications, although they may influence the decision on treatment. Diabetes mellitus is not a contraindication for thrombolytics either; rather, it may be considered in the overall management of the patient's health and may even be related to an increased risk of stroke. However, when assessing contraindications specifically related to thrombolytic therapy, a history of hemorrhagic stroke stands out as a critical concern.

A common contraindication for thrombolytic therapy in stroke patients is a history of hemorrhagic stroke. This condition poses significant risk when considering thrombolytic treatment because these medications work by dissolving blood clots that are obstructing blood flow to the brain. However, if a patient has previously experienced a hemorrhagic stroke, there is a heightened risk of re-bleeding or exacerbating any existing vascular vulnerabilities. Therefore, the presence of a history of hemorrhagic stroke necessitates careful consideration and often excludes a patient from receiving thrombolytic therapy, as the potential for severe complications is high.

Other factors such as age over 75 years or a history of previous ischemic stroke are not absolute contraindications, although they may influence the decision on treatment. Diabetes mellitus is not a contraindication for thrombolytics either; rather, it may be considered in the overall management of the patient's health and may even be related to an increased risk of stroke. However, when assessing contraindications specifically related to thrombolytic therapy, a history of hemorrhagic stroke stands out as a critical concern.